Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
First Claim
1. A method for increasing the storage life of platelets, said method comprising adding an amount of a mitochondrial enhancer to a fluid comprising said platelets, wherein said amount is effective to increase amount and/or rate of oxygen consumption of said platelets compared to amount and/or rate of oxygen consumption of platelets in a fluid to which mitochondrial enhancer has not been added, and wherein said amount is substantially non-toxic;
- wherein said mitochondrial enhancer is selected from the group consisting of endogenous alloxazines and non-endogenous alloxazines, and vitamin K1, vitamin K1 oxide, vitamin K2, vitamin K5, vitamin K6, vitamin K7, vitamin K-S (II) and vitamin L, whereby the storage life of the platelets is increased such that said platelets can be administered to a patient after seven days of storage.
7 Assignments
0 Petitions
Accused Products
Abstract
This invention provides methods for treating cellular blood components and other cells containing mitochondria to improve vital qualities of the cells by contacting the cells with a mitochondrial enhancer to the cells. Mitochondrial enhancers prevent damage to and rejuvenate mitochondria and cells containing mitochondria. Mitochondrial enhancers include alloxazines and related compounds, such as riboflavin. Cells are optionally treated with photoradiation to reduce pathogens with may be present, before, after, and/or during treatment with mitochondrial enhancer. Treating with mitochondrial enhancer enables utilization of higher photoradiation energies, which achieves better pathogen reduction. When platelets are treated with mitochondrial enhancer, treated platelets may be stored for longer times than untreated platelets before they are administered to patients.
-
Citations
39 Claims
-
1. A method for increasing the storage life of platelets, said method comprising adding an amount of a mitochondrial enhancer to a fluid comprising said platelets, wherein said amount is effective to increase amount and/or rate of oxygen consumption of said platelets compared to amount and/or rate of oxygen consumption of platelets in a fluid to which mitochondrial enhancer has not been added, and wherein said amount is substantially non-toxic;
- wherein said mitochondrial enhancer is selected from the group consisting of endogenous alloxazines and non-endogenous alloxazines, and vitamin K1, vitamin K1 oxide, vitamin K2, vitamin K5, vitamin K6, vitamin K7, vitamin K-S (II) and vitamin L, whereby the storage life of the platelets is increased such that said platelets can be administered to a patient after seven days of storage.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
-
34. A method for treating a fluid comprising platelets to reduce pathogens which may be present therein and to allow said platelets to be administered to a patient after being stored for seven days, said method comprising the steps of:
-
(a) adding a reduction-effective, substantially non-toxic amount of a photosensitizer to said fluid; (b) adding an amount of a mitochondrial enhancer different from said photosensitizerto said fluid;
wherein said amount is effective to increase amount and/or rate of oxygen consumption of said platelets compared to the amount and/or rate of oxygen consumption of platelets in a fluid to which mitochondrial enhancer has not been added, and wherein said amount is substantially non-toxic; and(c) exposing said fluid to photoradiation of sufficient energy to activate said photosensitizer, for a sufficient time to substantially reduce said pathogens; wherein said mitochondrial enhancer is selected from the group consisting of endogenous alloxazines and non-endogenous alloxazines, vitamin K1, vitamin K1 oxide, vitamin K2, vitamin K5, vitamin K6, vitamin K7, vitamin K-S (II) and vitamin L and said platelets can be administered to a patient after seven days of storage. - View Dependent Claims (35, 36, 37, 38, 39)
-
Specification